Hepatic encephalopathy: Suspect it early in patients with cirrhosis

Cleveland Clinic Journal of Medicine

Volumn 78, Issue 9, 2011, Pages 597-605

  Wakim Fleming, Jamilé ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; LACTULOSE;

DIFFERENTIAL DIAGNOSIS; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; OXIDATIVE STRESS; PATHOLOGY; REVIEW; RISK FACTOR; TIME;

DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LACTULOSE; LIVER CIRRHOSIS; OXIDATIVE STRESS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 80052802395     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78a10117     Document Type: Review

References (66)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35:716-721.
2. Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. J Hepatol 2008; 49:732-738.
3. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25(suppl 1):3-9.
4. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 2009; 50:2014-2021.
5. Norenberg MD, Jayakumar AR, Rama Rao KV, Panickar KS. New concepts in the mechanism of ammonia-induced astrocyte swelling. Metab Brain Dis 2007; 22:219-234.
6. Häussinger D, Görg B. Interaction of oxidative stress, astrocyte swelling and cerebral ammonia toxicity. Curr Opin Clin Nutr Metab Care 2010; 13:87-92.
7. Romero-Gómez M, Ramos-Guerrero R, Grande L, et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004; 41:49-54.
8. Tanigami H, Rebel A, Martin LJ, et al. Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats. Neuroscience 2005; 131:437- 449.
9. Llansola M, Rodrigo R, Monfort P, et al. NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab Brain Dis 2007; 22:321-335.
10. Montoliu C, Piedrafita B, Serra MA, et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol 2009; 43:272-279.
11. Desjardins P, Butterworth RF. The "peripheral-type" benzodiazepine (omega 3) receptor in hyperammonemic disorders. Neurochem Int 2002; 41:109-114.
12. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57:1156-1165.
13. Cauli O, Rodrigo R, Llansola M, et al. Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. Metab Brain Dis 2009; 24:69-80.
14. Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet 1995; 346:270-274.
15. Pomier-Layrargues G, Spahr L, Butterworth RF. Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 1995; 345:735.
16. Schliess F, Görg B, Häussinger D. RNA oxidation and zinc in hepatic encephalopathy and hyperammonemia. Metab Brain Dis 2009; 24:119-134.
17. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009; 104:1382-1389.
18. Hertz L, Kala G. Energy metabolism in brain cells: effects of elevated ammonia concentrations. Metab Brain Dis 2007; 22:199-218.
19. Marchesini G, Zoli M, Dondi C, et al. Prevalence of subclinical hepatic encephalopathy in cirrhotics and relationship to plasma amino acid imbalance. Dig Dis Sci 1980; 25:763-768.
20. Morgan MY, Milsom JP, Sherlock S. Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease. Gut 1978; 19:1068-1073.
21. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976; 80:77-91.
22. Poveda MJ, Bernabeu A, Concepción L, et al. Brain edema dynamicsin patients with overt hepatic encephalopathy A magnetic resonance imaging study. Neuroimage 2010; 52:481-487.
23. Bernthal P, Hays A, Tarter RE, Van Thiel D, Lecky J, Hegedus A. Cerebral CT scan abnormalities in cholestatic and hepatocellular disease and their relationship to neuropsychologic test performance. Hepatology 1987; 7:107-114.
24. Sugimoto R, Iwasa M, Maeda M, et al. Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy. Am J Gastroenterol 2008; 103:1413-1420.
25. Häussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2006; 43:1187-1190.
26. Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM 2008; 101:493-501.
27. Boyer TD, Haskal ZJ; American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010; 51:306.
28. García-Pagán JC, Caca K, Bureau C, et al; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370-2379.
29. Kircheis G, Knoche A, Hilger N, et al. Hepatic encephalopathy and fitness to drive. Gastroenterology 2009; 137:1706-1715.e1-9.
30. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50:1175-1183.
31. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000; 95:2029-2034.
32. Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96:2718-2723.
33. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30:890-895.
34. Murray KF, Carithers RL Jr; AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41:1407-1432.
35. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004; 19:253-267.
36. Weissenborn K. PHES: one label, different goods?! J Hepatol 2008; 49:308-312.
37. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45:549-559.
38. Parsons-Smith BG, Summerskill WHJ, Dawson AM, Sherlock S. The electroencephalograph in liver disease. Lancet 1957; 2:867-871.
39. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81-84.
40. Rovira A, Alonso J, Córdoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol 2008; 29:1612-1621.
41. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J; DGEM (German Society for Nutritional Medicine); ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25:285-294.
42. Gheorghe L, Iacob R, Vadan R, Iacob S, Gheorghe C. Improvement of hepatic encephalopathy using a modified high-calorie high-protein diet. Rom J Gastroenterol 2005; 14:231-238.
43. Weber FL Jr. Effects of lactulose on nitrogen metabolism. Scand J Gastroenterol Suppl 1997; 222:83-87.
44. Ojetti V, Lauritano EC, Barbaro F, et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 2009; 5:675-682.
45. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071-1081.
46. Blei AT, Córdoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001; 96:1968-1976.
47. Rothenberg ME, Keeffe EB. Antibiotics in the management of hepatic encephalopathy: an evidence-based review. Rev Gastroenterol Disord 2005; 5(suppl 3):26-35.
48. Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006; 136(suppl 1):295S-298S.
49. Egberts EH, Schomerus H, Hamster W, Jürgens P. [Branched-chain amino acids in the treatment of latent porto-systemic encephalopathy. A placebo-controlled double-blind cross-over study] [in German]. Z Ernahrungswiss 1986; 25:9-28.
50. Plauth M, Egberts EH, Hamster W, et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. J Hepatol 1993; 17:308-314.
51. Les I, Doval E, García-Martínez R, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 2011; 106:1081-1088.
52. Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol 2000; 95:3574-3578.
53. Schmid M, Peck-Radosavljevic M, König F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 2010; 30:574-582.
54. Blei AT. MARS and treatment of hepatic encephalopathy [in Spanish). Gastroenterol Hepatol 2005; 28:100-104.
55. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36:949-958.
56. Zidi SH, Zanditenas D, Gelu-Siméon M, et al. Treatment of chronic portosystemic encephalopathy in cirrhotic patients by embolization of portosystemic shunts. Liver Int 2007; 27:1389-1393.
57. Dhar R, Young GB, Marotta P. Perioperative neurological complications after liver transplantation are best predicted by pre-transplant hepatic encephalopathy. Neurocrit Care 2008; 8:253-258.
58. Teperman LW, Peyregne VP. Considerations on the impact of hepatic encephalopathy treatments in the pretransplant setting. Transplantation 2010; 89:771-778.
59. Rovira A, Córdoba J, Sanpedro F, Grivé E, Rovira-Gols A, Alonso J. Normalization of T2 signal abnormalities in hemispheric white matter with liver transplant. Neurology 2002; 59:335-341.
60. Senzolo M, Pizzolato G, Ferronato C, et al. Long-term evaluation of cognitive function and cerebral metabolism in liver transplanted patients. Transplant Proc 2009; 41:1295-1296.
61. Butterworth RF. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 2007; 22:309-320.
62. DiMartini A, Chopra K. The importance of hepatic encephalopathy: pre-transplant and post-transplant. Liver Transpl 2009; 15:121-123.
63. Saner FH, Nadalin S, Radtke A, Sotiropoulos GC, Kaiser GM, Paul A. Liver transplantation and neurological side effects. Metab Brain Dis 2009; 24:183-187.
64. Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 2009; 15:184-192.
65. Montagnese S, Middleton B, Skene DJ, Morgan MY. Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver Int 2009; 29:1372-1382.
66. Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol 2007; 102:744-753.